GLP-1 receptor agonist medications are currently being evaluated in major Alzheimer's disease clinical trials in non-overweight and non-obese populations.
"now we have the GLP-1 drugs like Ozempic, Mounjaro that are being tested in big Alzheimer's trials in thin people. You know, these are not obese or overweight; these are thin people, and because they have such potency of reducing brain inflammation" (said at 0:26:43)
Major Phase 3 clinical trials (evoke and evoke+) evaluated the GLP-1 receptor agonist semaglutide in large populations of patients with early-stage symptomatic Alzheimer's disease, enrolling participants based on amyloid positivity and cognitive impairment rather than elevated BMI or diabetes, thus including non-obese and normal-weight individuals. However, the Phase 3 trial results demonstrated that semaglutide did not slow clinical cognitive progression compared to placebo.
- supports: evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 stu… (Alzheimer's research & therapy 2025)
"evoke and evoke+ are randomized, double-blind, placebo-controlled phase 3 trials investigating the efficacy, safety, and tolerability of once-daily oral semaglutide versus placebo in early-stage symptomatic AD." (abstract, methods, passage verified)
pubmedfull study (doi) - context: Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic A… (Lancet (London, England) 2026)
"Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease." (abstract, conclusions, passage verified)
pubmedfull study (doi)